Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
Abstract: Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis.
Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
Type:
Grant
Filed:
December 29, 2009
Date of Patent:
December 13, 2011
Assignees:
Acorda Therapeutics, Inc., Beth Israel Deaconesss Medical Center, The Brigham and Women's Hospital, Inc.
Inventors:
Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
Type:
Grant
Filed:
May 17, 2010
Date of Patent:
September 27, 2011
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Robert Sklar, Mark Marchionni, David I. Gwynne
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Type:
Application
Filed:
July 17, 2009
Publication date:
July 7, 2011
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Anthony Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
Type:
Grant
Filed:
December 27, 2007
Date of Patent:
June 28, 2011
Assignees:
Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
Inventors:
Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
Type:
Grant
Filed:
July 3, 2008
Date of Patent:
June 28, 2011
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Anthony O. Caggiano, Gargi Roy, Rohini D'Souza
Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
Type:
Grant
Filed:
May 17, 2004
Date of Patent:
June 14, 2011
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
Abstract: Embodiments of the invention are directed to use of neuregulins to prevent or treat peripheral nerve injury, to attenuate, ameliorate or avoid the loss of peripheral nerve function.
Type:
Application
Filed:
October 14, 2010
Publication date:
May 26, 2011
Applicant:
ACORDA THERAPEUTICS INC.
Inventors:
ANTHONY O. CAGGIANO, ANTHONY J. BELLA, JENNIFER F. IACI
Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designed to treat a damaged heart in a patient.
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
Type:
Application
Filed:
June 4, 2010
Publication date:
September 23, 2010
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Anthony O. CAGGIANO, Jennifer IACI, Andrea VECCHIONE, Elizabeth MARKENSOHN
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
Type:
Grant
Filed:
December 18, 2008
Date of Patent:
June 8, 2010
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Markensohn
Abstract: The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
Type:
Grant
Filed:
October 10, 2007
Date of Patent:
May 25, 2010
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Anthony O. Caggiano, Andrea Vecchione, Jennifer Iaci
Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
Type:
Grant
Filed:
June 10, 2008
Date of Patent:
May 18, 2010
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Robert Sklar, Mark Marchionni, David I. Gwynne
Abstract: Disclosed herein are methods and compositions related to use of aminopyridines, such as fampridine, to improve impairments of patients with a demyelinating condition, such as MS.
Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
Type:
Grant
Filed:
August 22, 2003
Date of Patent:
February 16, 2010
Assignees:
Acorda Therapeutics, Inc., Beth Israel Deaconess Medical Center, The Brigham and Women's Hospital, Inc.
Inventors:
Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.
Type:
Grant
Filed:
July 30, 2007
Date of Patent:
June 2, 2009
Assignees:
Acorda Therapeutics, Inc., Ludwig Institute for Cancer Research
Inventors:
Andrew Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchioni, Mario Su Chen, Ian Hiles
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
Type:
Application
Filed:
December 18, 2008
Publication date:
April 23, 2009
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Markensohn